Spruce Biosciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0 | $4.9M | $10.1M | $0 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $19.5M | $46.4M | $49.4M | $35.2M |
| SG&A Expense | $17.0M | $14.6M | $12.7M | $12.1M |
| Operating Income | $-36.5M | $-56.2M | $-52.0M | $-47.3M |
| Operating Margin | — | -1,143.4% | -515.3% | — |
| Interest Expense | $90.0K | $307.0K | $483.0K | $420.0K |
| Pretax Income | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $-39.0M | $-53.0M | $-47.9M | $-46.2M |
| Net Margin | — | -1,079.9% | -475.0% | — |
| EPS (Basic) | $-50.83 | $-96.40 | $-1.24 | $-1.96 |
| EPS (Diluted) | $-50.83 | $-96.40 | $-1.24 | $-1.96 |
| Shares Outstanding (Basic) | 766.6K | 550.1K | 38.5M | 23.5M |
| Shares Outstanding (Diluted) | 766.6K | 550.1K | 38.5M | 23.5M |
| Dividends Per Share | — | — | — | — |